Can Nitrite AMPk Up Sirt-ainty to Treat Heart Failure with Preserved Ejection Fraction?

Circulation

Volumn 133, Issue 8, 2016, Pages 692-694

  Hsu, Steven ^a   Kass, David A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Editorials; glucose; heart failure; nitrites; protein kinases; signal transduction; sirtuins; stroke volume

Indexed keywords

ADENYLATE KINASE; CYCLIC GMP; ISOSORBIDE MONONITRATE; NITRATE; NITRITE; REACTIVE OXYGEN METABOLITE; SIRTUIN; SODIUM NITRITE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; SIRTUIN 3;

EDITORIAL; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANIMAL; HEART FAILURE; HEART STROKE VOLUME; HYPERGLYCEMIA; MALE; METABOLISM; PHYSIOLOGY;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; HEART FAILURE; HUMANS; HYPERGLYCEMIA; HYPERTENSION, PULMONARY; MALE; SIRTUIN 3; STROKE VOLUME;

EID: 84959143480     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.021409     Document Type: Editorial

References (20)

1. Sharma K, Kass DA. Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res. 2014;115:79-96. doi: 10.1161/CIRCRESAHA.115.302922.
2. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263-271. doi: 10.1016/j.jacc.2013.02.092.
3. Tedford RJ, Hassoun PM, Mathai SC, Girgis RE, Russell SD, Thiemann DR, Cingolani OH, Mudd JO, Borlaug BA, Redfield MM, Lederer DJ, Kass DA. Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation. 2012;125:289-297. doi: 10.1161/CIRCULATIONAHA.111.051540.
4. Lundberg JO, Gladwin MT, Weitzberg E. Strategies to increase nitric oxide signalling in cardiovascular disease. Nat Rev Drug Discov. 2015;14:623-641. doi: 10.1038/nrd4623.
5. van Heerebeek L, Hamdani N, Falcaõ-Pires I, Leite-Moreira AF, Begieneman MP, Bronzwaer JG, van der Velden J, Stienen GJ, Laarman GJ, Somsen A, Verheugt FW, Niessen HW, Paulus WJ. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012;126:830-839. doi: 10.1161/CIRCULATIONAHA.111.076075.
6. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11:214-222. doi: 10.1038/nm1175.
7. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E; RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268-1277. doi: 10.1001/jama.2013.2024.
8. Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tschöpe C, Leite-Moreira AF, Musters R, Niessen HWM, Linke WA, Paulus WJ, Hamdani N. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction (published online ahead of print December 7, 2015). JACC Heart Fail. doi: 10.1016/j.jchf.2015.10.007. http://www.sciencedirect.com/science/article/pii/S221317791500685X. Accessed January 31, 2016.
9. Lee DI, Zhu G, Sasaki T, Cho GS, Hamdani N, Holewinski R, Jo SH, Danner T, Zhang M, Rainer PP, Bedja D, Kirk JA, Ranek MJ, Dostmann WR, Kwon C, Margulies KB, Van Eyk JE, Paulus WJ, Takimoto E, Kass DA. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature. 2015;519:472-476. doi: 10.1038/nature14332.
10. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. doi: 10.1056/NEJMoa1409077.
11. Zamani P, Rawat D, Shiva-Kumar P, Geraci S, Bhuva R, Konda P, Doulias PT, Ischiropoulos H, Townsend RR, Margulies KB, Cappola TP, Poole DC, Chirinos JA. Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation. 2015;131:371-380; discussion 380. doi: 10.1161/CIRCULATIONAHA.114.012957.
12. Borlaug BA, Koepp KE, Melenovsky V. Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2015;66:1672-1682. doi: 10.1016/j.jacc.2015.07.067.
13. Omar SA, Fok H, Tilgner KD, Nair A, Hunt J, Jiang B, Taylor P, Chowienczyk P, Webb AJ. Paradoxical normoxia-dependent selective actions of inorganic nitrite in human muscular conduit arteries and related selective actions on central blood pressures. Circulation. 2015;131:381-389; discussion 389. doi: 10.1161/CIRCULATIONAHA.114.009554.
14. Lai Y-C, Tabima DM, Dube JJ, Hughan KS, Vanderpool RR, Goncharov DA, St Croix CM, Garcia-Ocana A, Goncharova EA, Tofovic SP, Mora AL, Gladwin MT. SIRT3-AMP-activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction. Circulation. 2016;133:717-731. doi: 10.1161/CIRCULATIONAHA.115.018935.
15. Lira VA, Soltow QA, Long JH, Betters JL, Sellman JE, Criswell DS. Nitric oxide increases GLUT4 expression and regulates AMPK signaling in skeletal muscle. Am J Physiol Endocrinol Metab. 2007;293:E1062-E1068. doi: 10.1152/ajpendo.00045.2007.
16. Kamga Pride C, Mo L, Quesnelle K, Dagda RK, Murillo D, Geary L, Corey C, Portella R, Zharikov S, St Croix C, Maniar S, Chu CT, Khoo NK, Shiva S. Nitrite activates protein kinase A in normoxia to mediate mitochondrial fusion and tolerance to ischaemia/reperfusion. Cardiovasc Res. 2014;101:57-68. doi: 10.1093/cvr/cvt224.
17. Hamdani N, Franssen C, Lourenço A, Falcaõ-Pires I, Fontoura D, Leite S, Plettig L, López B, Ottenheijm CA, Becher PM, González A, Tschöpe C, Diéz J, Linke WA, Leite-Moreira AF, Paulus WJ. Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. Circ Heart Fail. 2013;6:1239-1249. doi: 10.1161/CIRCHEARTFAILURE.113.000539.
18. Matsushima S, Sadoshima J. The role of sirtuins in cardiac disease. Am J Physiol Heart Circ Physiol. 2015;309:H1375-H1389. doi: 10.1152/ajpheart.00053.2015.
19. Cheung KG, Cole LK, Xiang B, Chen K, Ma X, Myal Y, Hatch GM, Tong Q, Dolinsky VW. Sirtuin-3 (SIRT3) protein attenuates doxorubicininduced oxidative stress and improves mitochondrial respiration in H9c2 cardiomyocytes. J Biol Chem. 2015;290:10981-10993. doi: 10.1074/jbc. M114.607960.
20. Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WH, McNulty SE, Velazquez EJ, Shah MR, Braunwald E; NHLBI Heart Failure Clinical Research Network. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med. 2015;373:2314-2324. doi: 10.1056/NEJMoa1510774.